Skip to main content
Back
ARVN logo

Arvinas, Inc.

Data quality: 100%
Oversold
ARVN
NASDAQ Healthcare Biotechnology
$10.32
▼ $0.62 (-5.67%)
Mkt Cap: 662.79M
Day Range
$10.32 $11.21
52-Week Range
$5.90 $14.51
Volume
868,056
50D / 200D Avg
$12.71 / $10.01
Prev Close
$10.94

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E -8.2 0.4
P/B 1.5 2.9
ROE % -16.2 3.8
Net Margin % -30.8 3.9
Rev Growth 5Y % 48.8 10.0
D/E 0.0 0.2

Key Takeaways

Revenue grew 48.78% annually over 5 years — strong growth
Debt/Equity of 0.02 — conservative balance sheet
Negative free cash flow of -275.70M
PEG of 0.18 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 49.08%
Capital efficient — spends only 0.72% of revenue on capex

Growth

Revenue Growth (5Y)
48.78%
Revenue (1Y)-0.30%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-16.23%
ROIC-19.48%
Net Margin-30.77%
Op. Margin-43.75%

Safety

Debt / Equity
0.02
Current Ratio4.92
Interest Coverage0.00

Valuation

P/E Ratio
-8.20
P/B Ratio1.53
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -0.30% Revenue Growth (3Y) 82.90%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 48.78% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 262.60M Net Income (TTM) -80.80M
ROE -16.23% ROA -11.26%
Gross Margin 98.02% Operating Margin -43.75%
Net Margin -30.77% Free Cash Flow (TTM) -275.70M
ROIC -19.48% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.02 Current Ratio 4.92
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -8.20 P/B Ratio 1.53
P/S Ratio 2.52 PEG Ratio 0.18
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 662.79M Enterprise Value 528.39M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 262.60M 263.40M 78.50M 131.40M 53.60M
Net Income -80.80M -198.90M -367.30M -282.50M -191.00M
EPS (Diluted) -1.28 -2.77 -6.62 -5.31 -3.82
Gross Profit 257.40M 263.40M 78.50M 131.40M 53.60M
Operating Income -114.90M -250.20M -401.50M -263.20M -188.40M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 717.90M 1.09B 1.30B 1.27B 1.58B
Total Liabilities 284.00M 529.70M 644.60M 703.90M 799.90M
Shareholders' Equity 433.90M 561.70M 660.00M 564.90M 781.70M
Total Debt 8.50M 9.70M 3.20M 5.50M 5.00M
Cash & Equivalents 142.90M 100.50M 311.70M 81.30M 108.30M
Current Assets 700.70M 1.07B 1.28B 1.24B 1.55B
Current Liabilities 142.50M 229.80M 257.10M 295.10M 261.70M